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Abstract: The use of nanotechnology in medicine and more speciﬁ  cally drug delivery is set to 
spread rapidly. Currently many substances are under investigation for drug delivery and more 
speciﬁ  cally for cancer therapy. Interestingly pharmaceutical sciences are using nanoparticles to 
reduce toxicity and side effects of drugs and up to recently did not realize that carrier systems 
themselves may impose risks to the patient. The kind of hazards that are introduced by using 
nanoparticles for drug delivery are beyond that posed by conventional hazards imposed by 
chemicals in classical delivery matrices. For nanoparticles the knowledge on particle toxicity 
as obtained in inhalation toxicity shows the way how to investigate the potential hazards of 
nanoparticles. The toxicology of particulate matter differs from toxicology of substances as 
the composing chemical(s) may or may not be soluble in biological matrices, thus inﬂ  uencing 
greatly the potential exposure of various internal organs. This may vary from a rather high local 
exposure in the lungs and a low or neglectable exposure for other organ systems after inhalation. 
However, absorbed species may also inﬂ  uence the potential toxicity of the inhaled particles. 
For nanoparticles the situation is different as their size opens the potential for crossing the vari-
ous biological barriers within the body. From a positive viewpoint, especially the potential to 
cross the blood brain barrier may open new ways for drug delivery into the brain. In addition, 
the nanosize also allows for access into the cell and various cellular compartments including 
the nucleus. A multitude of substances are currently under investigation for the preparation of 
nanoparticles for drug delivery, varying from biological substances like albumin, gelatine and 
phospholipids for liposomes, and more substances of a chemical nature like various polymers 
and solid metal containing nanoparticles. It is obvious that the potential interaction with tissues 
and cells, and the potential toxicity, greatly depends on the actual composition of the nanoparticle 
formulation. This paper provides an overview on some of the currently used systems for drug 
delivery. Besides the potential beneﬁ  cial use also attention is drawn to the questions how we 
should proceed with the safety evaluation of the nanoparticle formulations for drug delivery. 
For such testing the lessons learned from particle toxicity as applied in inhalation toxicology 
may be of use. Although for pharmaceutical use the current requirements seem to be adequate 
to detect most of the adverse effects of nanoparticle formulations, it can not be expected that 
all aspects of nanoparticle toxicology will be detected. So, probably additional more speciﬁ  c 
testing would be needed.
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Introduction
Recent years have witnessed unprecedented growth of research and applications in the 
area of nanoscience and nanotechnology. There is increasing optimism that nanotech-
nology, as applied to medicine, will bring signiﬁ  cant advances in the diagnosis and 
treatment of disease. Anticipated applications in medicine include drug delivery, both 
in vitro and in vivo diagnostics, nutraceuticals and production of improved biocompat-
ible materials (Duncan 2003; De Jong et al 2005; ESF 2005; European Technology 
Platform on Nanomedicine 2005; Ferrari 2005). Engineered nanoparticles are an International Journal of Nanomedicine 2008:3(2) 134
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important tool to realize a number of these applications. It 
has to be recognized that not all particles used for medical 
purposes comply to the recently proposed and now generally 
accepted deﬁ  nition of a size 100 nm (The Royal Society 
and Royal Academy of Engineering 2004). However, this 
does not necessarily has an impact on their functionality in 
medical applications. The reason why these nanoparticles 
(NPs) are attractive for medical purposes is based on their 
important and unique features, such as their surface to mass 
ratio that is much larger than that of other particles, their 
quantum properties and their ability to adsorb and carry other 
compounds. NPs have a relatively large (functional) surface 
which is able to bind, adsorb and carry other compounds such 
as drugs, probes and proteins. However, many challenges 
must be overcome if the application of nanotechnology is to 
realize the anticipated improved understanding of the patho-
physiological basis of disease, bring more sophisticated diag-
nostic opportunities, and yield improved therapies. Although 
the deﬁ  nition identiﬁ  es nanoparticles as having dimensions 
below 0.1 µm or 100 nm, especially in the area of drug 
delivery relatively large (size 100 nm) nanoparticles may 
be needed for loading a sufﬁ  cient amount of drug onto the 
particles. In addition, for drug delivery not only engineered 
particles may be used as carrier, but also the drug itself may 
be formulated at a nanoscale, and then function as its own 
“carrier” (Cascone et al 2002; Baran et al 2002; Duncan 2003; 
Kipp 2004). The composition of the engineered nanoparticles 
may vary. Source materials may be of biological origin like 
phospholipids, lipids, lactic acid, dextran, chitosan, or have 
more “chemical” characteristics like various polymers, 
carbon, silica, and metals. The interaction with cells for 
some of the biological components like phospholipids will 
be quite different compared to the non biological components 
such as metals like iron or cadmium. Especially in the area 
of engineered nanoparticles of polymer origin there is a vast 
area of possibilities for the chemical composition.
Although solid NPs may be used for drug targeting, when 
reaching the intended diseased site in the body the drug car-
ried needs to be released. So, for drug delivery biodegradable 
nanoparticle formulations are needed as it is the intention 
to transport and release the drug in order to be effective. 
However, model studies to the behavior of nanoparticles 
have largely been conducted with non-degradable particles. 
Most data concerning the biological behavior and toxicity 
of particles comes from studies on inhaled nanoparticles as 
part of the unintended release of ultraﬁ  ne or nanoparticles 
by combustion derived processes such as diesel exhaust par-
ticles (reviewed by Oberdörster 1996; Donaldson et al 2001, 
2004; Borm 2002; Donaldson and Stone 2003; Dreher 2004; 
Kreyling et al 2004; Oberdörster, Oberdörster et al 2005). 
Research has demonstrated that exposure to these combustion 
derived ultraﬁ  ne particles/nanoparticles is associated with 
a wide variety of effects (Donaldson et al 2005) including 
pulmonary inﬂ  ammation, immune adjuvant effects (Granum 
and Lovik 2002) and systemic effects including blood 
coagulation and cardiovascular effects (Borm and Kreyling 
2004; Oberdorster, Oberdörster et al 2005). Since the cut-
off size for both ultraﬁ  ne and nanoparticles (100 nm) is the 
same, now both terms are used as equivalent. Based on the 
adverse effects of ultraﬁ  ne particles as part of environmental 
pollution, engineered nanoparticles may be suspected of hav-
ing similar adverse effects. It is the purpose of this review 
to use this database on combustion derived nanpoarticles 
(CDNP) obtained by inhalation toxicology and epidemiology 
and bridge the gap to engineered nanoparticles.
Nanoparticles and drug delivery
Drug delivery and related pharmaceutical development 
in the context of nanomedicine should be viewed as sci-
ence and technology of nanometer scale complex systems 
(10–1000 nm), consisting of at least two components, one 
of which is a pharmaceutically active ingredient (Duncan 
2003; Ferrari 2005), although nanoparticle formulations of 
the drug itself are also possible (Baran et al 2002; Cascone 
et al 2002; Duncan 2003; Kipp 2004). The whole system 
leads to a special function related to treating, preventing 
or diagnosing diseases sometimes called smart-drugs 
or theragnostics (LaVan et al 2003). The primary goals 
for research of nano-bio-technologies in drug delivery 
include:
•  More speciﬁ  c drug targeting and delivery,
•  Reduction in toxicity while maintaining therapeutic 
effects,
•  Greater safety and biocompatibility, and
•  Faster development of new safe medicines.
The main issues in the search for appropriate carriers as 
drug delivery systems pertain to the following topics that 
are basic prerequisites for design of new materials. They 
comprise knowledge on (i) drug incorporation and release, 
(ii) formulation stability and shelf life (iii) biocompatibility, 
(iv) biodistribution and targeting and (v) functionality. In 
addition, when used solely as carrier the possible adverse 
effects of residual material after the drug delivery should be 
considered as well. In this respect biodegradable nanopar-
ticles with a limited life span as long as therapeutically 
needed would be optimal.International Journal of Nanomedicine 2008:3(2) 135
Drug delivery and nanoparticles
Table 1 presents some of the types of chemical structures 
and possibilities for the preparation of nanoscale materials 
used as pharmaceutical carrier system (reviewed in Borm 
and Muller-Schulte 2006). Certainly none of the so far 
developed carriers fulﬁ  ll all the parameters mentioned above 
to the full extent; the progress made in nanotechnology inter 
alia emerging from the progress in the polymer-chemistry, 
however, can provide an intriguing basis to tackle this issue 
in a promising way.
The aims for nanoparticle entrapment of drugs are either 
enhanced delivery to, or uptake by, target cells and/or a reduc-
tion in the toxicity of the free drug to non-target organs. Both 
situations will result in an increase of therapeutic index, the 
margin between the doses resulting in a therapeutic efﬁ  cacy 
(eg, tumor cell death) and toxicity to other organ systems. For 
these aims, creation of long-lived and target-speciﬁ  c nanopar-
ticles is needed. Chemical formulations under investigation are 
shown in Table 2. Most of the compounds are biodegradable 
polymers resulting in drug release after degradation. One of 
the problems in the use of particulate drug carriers including 
nanomaterials is the entrapment in the mononuclear phagocytic 
system as present in the liver and spleen (Lenaerts et al 1984; 
Gibaud et al 1996; Demoy et al 1997; Moghimi et al 2001). 
However, liver targeting of nanoparticles may be favorable 
when treating liver diseases like tumor metastasis or hepa-
titis. Surface modiﬁ  cation with polyethylene glycol (PEG) 
resulted in prolonged presence in the circulation by inhibiting 
recognition and phagocytosis by the mononuclear phagocytic 
system (Bazile et al 1995; Peracchia et al 1999; Niidome 
et al 2006). In addition to altering the distribution the PEG 
modiﬁ  cation also reduced in vitro toxicity when gold nanorods 
were modiﬁ  ed using PEG (Niidome et al 2006). Coating of 
NP may also be needed to prevent agglomeration. Several 
coatings can be used to prevent agglomeration and keeping the 
particles in colloidal suspension including various polymers 
like polyethylene glycol (PEG), poly(vinylpyrrolidone) (PVP) 
etc, natural polymers like dextran, chitosan, pullulan etc, and 
surfactants like sodium oleate, dodecylamine etc (reviewed 
by Gupta and Gupta 2005).
NP size can influence the NP distribution as was 
demonstrated for lipid vesicles for which a lower liver uptake 
was found for the smaller vesicles (200/300 nm versus 
25/50 nm) (Seki et al 2004). Even small size differences may be 
of inﬂ  uence for the actual distribution and thus bioavailability 
(Saez et al 2000; Fishbein et al 2001; Shim et al 2004; Zhang 
et al 2004; Fang et al 2006). For liposomes with sizes 100 nm 
the clearance rate by the mononuclear phagocytic system 
increased with increasing size, while for sizes below 100 nm 
charge was more important (Senior and Gregoriadis 1982; 
Senior et al 1985). However, not all particles with sizes below 
100 nm will behave similarly and composition will be important 
as well. Analogous to earlier ﬁ  ndings on asbestiform and 
mineral ﬁ  bers, the actual size and shape of nanomaterials will 
be of importance.
Besides degradation physical means such as heating 
and light may be used to provoke the therapeutic effect 
Table 1 Overview of nanoparticles and their applications in Life 
Sciences
Particle class  Materials  Application
Natural   Chitosan  Drug/Gene delivery
materials or  Dextrane 
derivatives Gelatine 
 Alginates 
 Liposomes 
 Starch 
Dendrimers  Branched polymers  Drug delivery
Fullerenes  Carbon based carriers  Photodynamics
   Drug  delivery
Polymer carriers  Polylactic acid  Drug/gene delivery
 Poly(cyano)acrylates 
 Polyethyleinemine 
 Block  copolymers 
 Polycaprolactone 
Ferroﬂ  uids  SPIONS  Imaging (MRI)
 USPIONS 
Quantum dots  Cd/Zn-selenides  Imaging
    In vitro diagnostics
Various Silica-nanoparticles  Gene  delivery
  Mixtures of above
Table 2 Chemicals under investigation for drug delivery
Albumin  Damascelli et al 2003
Cetyl alcohol/polysorbate  Koziara et al 2004
Chitosan  Dyer et al 2002;
  Huang et al 2004
Gelatin  Cascone et al 2002
Gold Hainﬁ  eld et al 2004;
  Paciotti et al 2004
Hydrogels  Gupta and Gupta 2004
Magnetic iron oxide  Gupta and Gupta 2005
Methoxy   Kim et al 2003
poly(ethylene glycol)/poly(ε-caprolactone)
Polyalkylcyanoacrylate composites  Alyautdin et al 1997;
  Kreuter et al 2003
Poly(D,L-lactic-co-glycolic)acid (PLGA)  Panyam et al 2002;
  Weissenbrock et al 2004
Solid lipid formulations  Muller et al 2000;
  Wissing et al 2004International Journal of Nanomedicine 2008:3(2) 136
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(cell death) or for local drug release, respectively. 
Thermosensitive nanoparticles may be used for selective 
release of the content after speciﬁ  c localization. An example 
of this principle is presented in Figure 1. For doxorubicin 
an enhanced cytotoxicity was observed in vitro at 42 oC 
compared to 37 oC using copolymers of polyethylene glycol 
(PEG) and poly-L-lactide (PLLA) (Na et al 2006). In addi-
tion, the release of photosensitizers from nanoformulations 
by light, so called photodynamic therapy, was able to induce 
cytotoxicity as demonstrated for PLGA nanoparticles con-
taining zinc(II)phthalocyanine (Ricci-Junior and Marchetti 
2006) and indocyanine green (Gomes et al 2006).
Use of NP formulations in drug delivery
One of the major challenges in drug delivery is to get the drug 
at the place it is needed in the body thereby avoiding potential 
side effects to non diseased organs. This is especially chal-
lenging in cancer treatment where the tumor may be localized 
as distinct metastases in various organs. The non restricted 
(cyto)toxicity of chemotherapeutics thus limits the full use 
of their therapeutic potential. Local drug delivery or drug 
targeting results in increased local drug concentrations and 
provides strategies for more speciﬁ  c therapy. Nanoparticles 
have speciﬁ  c particles as tools to enable these strategies. 
These include beneﬁ  ts such as their small size which allows 
penetration of cell membranes, binding and stabilization of 
proteins, and lysosomal escape after endocytosis.
The entrapment of chemotherapeutics in nanosized for-
mulations like liposomes has been already subject of study 
for considerable time (reviews: Crommelin and Storm 2003; 
Metselaar and Storm 2005; Minko et al 2006). Liposomes as 
nanosized phospholipid “fatty” structures have the advantage 
of being small, ﬂ  exible and biocompatible thus being able 
to pass along the smallest arterioles and endothelial fenes-
trations without causing clotting. Now also other materials, 
including various (co-)polymers and dendrimers at the 
nanosize range have become available to alter the distribution 
of encapsulated or attached drugs.
One of the therapeutics under intensive study is paclitaxel 
(taxol). For paclitaxel the nanoparticle formulation resulted 
in enhanced cytotoxicity for tumor cells in vitro, and at the 
same time an increased sustainable therapeutic efﬁ  cacy in 
an in vivo animal model (Win and Feng 2006). The pacli-
taxel was encapsulated in vitamin E TPGS-emulsiﬁ  ed poly 
(D,L-lactic-co-glycolic acid) (PLGA) nanoparticles, and this 
system resulted in a higher and prolonged level above the 
effective concentration in vivo, reﬂ  ected in an increased area 
under the curve (AUC)
Apart from size the surface chemistry of particles is of 
crucial importance in particle uptake, distribution and effects. 
Figure 1 Graph illustrating contactless controllable drug carrying system based on thermosensitive magnetic nano- and micro particles. The insert shows the application of 
the system with Rhodamine B encapsulated beads that is released after heating up to 45 oC.International Journal of Nanomedicine 2008:3(2) 137
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This was shown extensively with acute and chronic models of 
surface modiﬁ  ed micro quartzes (Schins et al 2002; Albrecht 
et al 2005). Quartz which was coated with PVNO-polymer 
was taken op by macrophages without toxicity and showed no 
genotoxicity in epithelial cells or acute and chronic inﬂ  amma-
tion. On the other hand naïve quartz caused these effects to a 
large extent. An altered body distribution was demonstrated 
for two types of polymer particles (Tomazic-Jezic et al 2001). 
Only PMMA (about 1.4 µm and about 6.4 µm) particles but 
not PS (about 1.2 µm, 5.2 µm and 12.5 µm) particles could 
be recovered form the spleen after intraperitoneal administra-
tion (Tomazic-Jezic et al 2001). Whether a similar situation 
exists for nanoparticles is unknown, but studies with surface 
modiﬁ  ed polystyrene particles do suggest different effects 
on blood coagulation (Nemmar et al 2003), mitochondrial 
ROS formation and cellular oxidative burst (Xia et al 2006). 
In addition, as mentioned above the coating of nanoparticles 
with polyethylene glycol (PEG) increases the time in circula-
tion for the nanoparticles (Bazile et al 1995; Peracchia et al 
1999; Niidome et al 2006).
The aims for nanoparticle entrapment of drugs are either 
enhanced delivery to, or uptake by, target cells and/or a 
reduction in the toxicity of the free drug to non-target organs. 
For these aims, creation of long-lived and target-speciﬁ  c 
nanoparticles is needed. One of the problems is the entrap-
ment of nanoparticles in the mononuclear phagocytic system 
as present in the liver and spleen (Lenaerts et al 1984; Gibaud 
et al 1996; Demoy et al 1997; Moghimi et al 2001). How-
ever, liver targeting of nanoparticles may be favorable when 
treating liver diseases like tumor metastasis or hepatitis. Also 
oligonucleotides for modiﬁ  cation of gene expression were 
demonstrated to migrate into the liver when bound to biode-
gradable polyalkylcyanoacrylate nanoparticles (Fattal et al 
1998). Surface modiﬁ  cation with PEG resulted in prolonged 
presence in the circulation by inhibiting recognition and 
phagocytosis by the mononuclear phagocytic system (Bazile 
et al 1995; Peracchia et al 1999; Niidome et al 2006). Besides 
reduction of therapeutic efﬁ  cacy, liver entrapment may also 
have an adverse effect on liver function. For cyanoacrylate 
and polystyrene nanoparticles (about 214 nm and about 128 
nm, respectively) transient liver alterations were observed 
after acute and chronic intravenous administration (Fernan-
dez-Urrusuno et al 1995, 1997). Inﬂ  ammatory responses 
were characterized by secretion of acute phase protein 
α1-acid glycoprotein by hepatocytes (Fernandez-Urrusuno 
et al 1995). In addition, antioxidant defenses of hepatocytes 
were depleted probably as a result of local release of oxida-
tive species (Fernandez-Urrusuno et al 1997).
Although nanoformulation is aimed at enhancing drug 
delivery without loss of drug activity, in a study comparing 
insulin-chitosan nanoparticles to chitosan solution and chitosan 
powder formulations the insulin-chitosan nanoparticles were 
less effective in terms of bioavailability and lowering blood glu-
cose level in both a rat and sheep model (Dyer et al 2002).
Cellular and intracellular targets
For drug delivery not only organ or cellular targeting is of 
importance but also the fate of the nanoparticles within the 
cells. Particles generally end intracellularly in endosomes or 
lysosomes followed by degradation. For activity of the encap-
sulated drugs release into the cytosol is needed. However, 
for nanoparticles of about 20 nm also cellular uptake without 
contribution by endocytic mechanisms was demonstrated 
(Edetsberger et al 2005). Chemical characteristics such as 
surface charge may also determine the fate of nanoparticles 
in cells. Surface functionalization of gold nanoparticles with 
PEG resulted in efﬁ  cient internalization in endosomes and 
cytosol, and localized in the nuclear region (Shenoy et al 
2006). Poly(DL-lactide-co-glycolide) nanoparticles were 
found to be ingested by cells by endocytosis (Panyam et al 
2002; Konan et al 2003). The escape from these endosomes 
into the cellular cytoplasm was suggested to be caused by 
a change in surface charge form negative to positive of the 
PLGA nanoparticles resulting in cytoplasmic delivery of 
the incorporated drugs. The hypothesis that the positive 
surface charge inﬂ  uenced the escape of the endosomes 
was supported by data obtained with negatively charged 
polystyrene nanoparticles which did not reach the cytosol 
but remained in the endosomal compartment of the smooth 
muscle cells used in this study (Panyam et al 2002).
Speciﬁ  c targeting to retinal pigment epithelium cells 
in the eye is possible (Bourges et al 2003). Very small 
quantum dots (10 nm) have been used for specific 
targeting of peptide coated dots to the vasculature of lungs 
and tumors (Åkerman et al 2002). In addition, polymer 
shells on the quantum dots might be linked to targeting 
molecules. For example quantum dots cores can be coated 
with hydrophilic polyethylene glycol (PEG) to increase the 
half life time (Ballou et al 2004). However, also uptake by 
lymph nodes was demonstrated in which the quantum dots 
could be observed up until 4 months after administration, 
so accumulation seems likely (Ballou et al 2004). PEG 
coating abrogated uptake by the reticuloendothelial system 
of liver and spleen. In contrast about 40–50 nm magnetic 
nanoparticles coated with PEG were quite well taken up by 
endocytosis (Gupta and Curtis 2004).International Journal of Nanomedicine 2008:3(2) 138
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Surface modiﬁ  cations of nanoparticles offer possibilities 
for medical applications like drug targeting in terms 
of cellular binding, uptake and intracellular transport. 
Carbohydrate binding ligands on the surface of biodegrad-
able and biocompatible poly(D,L-lactic-co-glycolide)acid 
(PLGA) nanospheres were found to increase cellular bind-
ing (Weissenböck et al 2004). Such increased adherence 
may lead to an enhanced activity of the drug presented as or 
incorporated in nanoparticles. Coupling speciﬁ  c proteins such 
as antibodies to the nanoparticle surface may enable a more 
speciﬁ  c immunologically directed targeting of the particles 
(Nobs et al 2004; Prinzen et al 2007).
The Brain – the ultimate target for drug 
delivery
From several perspectives the brain is a challenging organ for 
drug delivery. First, the incidence of degenerative diseases in 
the brain will increase with the aging population. Secondly, 
the blood brain barrier (BBB) is well-known as the best 
gatekeeper in the body toward exogenous substances (review 
Pardridge 2007). Generally pharmaceuticals including most 
small molecules do not cross the BBB. The endothelial 
barrier is speciﬁ  cally tight at the interface with the brain 
astrocytes and can in normal conditions only be passed 
using endogeneous BBB transporters resulting in carrier 
mediated transport, active efﬂ  ux transport and/or receptor 
mediated transport. However the barrier properties may 
be compromised intentionally or unintentionally by drug 
treatment allowing passage of nanoparticles (Olivier et al 
1999; Kreuter et al 2003; Lockman et al 2003; Koziara et al 
2006). The delivery of drugs by nanocarrier was recently 
reviewed (Koziara et al 2006; Tiwari and Amiji 2006).
Passage of the BBB was suggested to be possible by 
the toxic effect of nanoparticles (about 200 nm) on cerebral 
endothelial cells (Olivier et al 1999), although for similar 
nanoparticles (about 300 nm) this was contradicted in another 
study (Kreuter et al 2003). In addition this effect was not 
found for a different type of nanoparticles (Lockman et al 
2003). Physical association of the drug to the nanoparticles 
was necessary for drug delivery to occur into the brain 
(Kreuter et al 2003). When nanoparticles with different 
surface characteristics were evaluated, neutral nanoparticles 
and low concentrations of anionic nanoparticles were found 
to have no effect on BBB integrity, whereas high concen-
trations of anionic nanoparticles and cationic nanoparticles 
were toxic for the BBB. The extent of brain uptake of anionic 
nanoparticles at lower concentrations was superior to neu-
tral or cationic formulations at the same concentrations. 
So, nanoparticle surface charges must be considered for 
toxicity and brain distribution proﬁ  les (Lockman et al 2004). 
Especially coating of the nanoparticles with the polysorbate 
(Tween) surfactants resulted in transport of drugs across 
the blood brain barrier (Kreuter 2004). The mechanism 
for transport was suggested to be endocytosis via the Low 
Density Lipoprotein (LDL) receptor of the endothelial cells 
after adsorption of lipoproteins form blood plasma to the 
nanoparticles (Kreuter 2001, 2004). Additional investigations 
revealed the role of apolipoprotein-E for transport of drugs 
across the BBB while apolipoprotein-E variants that did not 
recognized lipoprotein receptors failed in transporting the 
drug across the BBB (Michaelis et al 2006). It was suggested 
that the recognition and interaction with lipoprotein receptors 
on brain capillary endothelial cells was responsible for the 
brain uptake of the drug.
Passage of the BBB may also be achieved by mask-
ing certain drug characteristics preventing or limiting 
binding to cellular efﬂ  ux systems like p-glycoprotein, a 
cellular transporter associated with drug removal from 
cells. P-glycoprotein is one of the ATP dependent efﬂ  ux 
transporters that has an important physiological role in limit-
ing drug entry into the brain (Girardin 2006; Sharom 2006). 
In addition, p-glycoprotein also designated the multidrug 
resistance protein may be highly expressed in drug resistant 
tumor cells. Surfactant coated poly(butyl)cyanoacrylate 
nanoparticles have been used to deliver drugs to the CNS 
(Alyautdin et al 1997) The effect of entrapment of a cyto-
toxic drug paclitaxel (PX) in cetyl alcohol/polysorbate 
nanoparticles (PX NP) was evaluated in an in situ rat brain 
perfusion model (Koziara et al 2004). The results suggest 
that entrapment of paclitaxel in nanoparticles signiﬁ  cantly 
increases the brain drug uptake and its toxicity towards 
p-glycoprotein expressing tumor cells (p-glycoprotein is 
an efﬂ  ux transporter associated with drug removal from 
the cells). It was hypothesized that PX nanoparticles limit 
paclitaxel binding to p-glycoprotein and subsequent efﬂ  ux 
from the cells, which consequently would lead to higher brain 
and tumor cell levels.
Other routes for reaching the brain, circumventing the 
BBB, may be via migration along the olfactory or trigeminal 
nerve endings after deposition on the olfactory mucosa in 
the nasal region (Oberdörster et al 2004). Translocation of 
ultraﬁ  ne 13C particles (35 nm) was detected by using this 
isotope measurement in the brain olfactory bulb after inha-
lation exposure. Also other solid NP like manganese oxide 
was shown to translocate to the brain by the olfactory route 
(Elder et al 2006), based on measurements of manganese in International Journal of Nanomedicine 2008:3(2) 139
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different parts of the brain. In order to increase the speciﬁ  c 
uptake via the inhalation route nanoparticles have been 
functionalized by conjugation with bioactive ligands-lectins 
to the surface of poly (ethylene glycol)- poly (lactid acid) 
(PEG-PLA) nanoparticles. Wheat germ agglutinin (WGA) 
was used which binds to N-acetyl-D-glucosamine and sialic 
acid both of which are abundantly present in the nasal cavity. 
There was a twofold increase in the brain uptake of such 
functionalized NP (Gao et al 2006). However, it needs to be 
stated that both passage of the BBB and the olfactory route 
only account for up to 2% nanoparticles uptake, and its efﬁ  -
cacy with regard to drug delivery needs to make considerable 
increments before use.
Toxicological hazards of nanoparticles
General concepts
To use the potential of Nanotechnology in Nanomedicine, 
full attention is needed to safety and toxicological issues. For 
pharmaceuticals speciﬁ  c drug delivery formulations may be 
used to increase the so called therapeutic ratio or index being 
the margin between the dose needed for clinical efﬁ  cacy and 
the dose inducing adverse side effects (toxicity). However, 
also for these speciﬁ  c formulations a toxicological evalua-
tion is needed. This is particularly true for the applications of 
nanoparticles for drug delivery. In these applications particles 
are brought intentionally into the human body and environ-
ment, and some of these new applications are envisaged an 
important improvement of health care (Buxton et al 2003; 
European Technology Platform on Nanomedicine 2005; 
Ferrari 2005). Opinions started to divert when toxicologists 
claimed that new science, methods and protocols are needed 
(Borm 2002; Nel et al 2006). However, the need for this 
is now underlined by several expert reports (Oberdörster, 
Maynard et al 2005; SCENIHR 2006) and more importantly 
by the following concepts:
1.  Nanomaterials are developed for their unique (surface) 
properties in comparison to bulk materials. Since surface 
is the contact layer with the body tissue, and a crucial 
determinant of particle response, these unique properties 
need to be investigated from a toxicological standpoint. 
When nanoparticles are used for their unique reactive 
characteristics it may be expected that these same char-
acteristics also have an impact on the toxicity of such 
particles. Although current tests and procedures in drug 
and device evaluation may be appropriate to detect many 
risks associated with the use of these nanoparticles, it can-
not be assumed that these assays will detect all potential 
risks. So, additional assays may be needed. (SCENIHR 
2006) This may differ depending on the type of particles 
used, ie, biological versus non-biological origin.
2.  Nanoparticles are attributed qualitatively different 
physico-chemical characteristics from micron-sized 
particles, which may result in changed body distribu-
tion, passage of the blood brain barrier, and triggering 
of blood coagulation pathways. In view of these charac-
teristics speciﬁ  c emphasis should be on investigations in 
(pharmaco)kinetics and distribution studies of nanopar-
ticles. What is currently lacking is a basic understanding 
of the biological behavior of nanoparticles in terms of 
distribution in vivo both at the organ and cellular level.
3.  Effects of combustion derived nanoparticles in environ-
mentally exposed populations mainly occur in diseased 
individuals. Typical pre-clinical screening is almost 
always done in healthy animals and volunteers and risks 
of particles may therefore be detected at a very late 
stage.
It may be argued that some if not all of these speciﬁ  c effects 
will be detected during routine testing and post marketing 
evaluation after clinical use. All would depend on the types 
of assays used in the preclinical evaluation, which should 
be considered in the light of the use of the ﬁ  nal products. In 
addition, one cannot rely on the toxicological proﬁ  le of the 
bulk material when that material is used in a nanoformulation. 
What is clear is that the safety evaluation and the risk beneﬁ  t 
analysis need to be performed on a case by case basis.
The use of nanoparticles as drug carrier may reduce the 
toxicity of the incorporated drug. In general the toxicity of 
the whole formulation is investigated while results of the 
nanoparticles itself are not described. So, discrimination 
between drug and nanoparticle toxicity cannot be made. 
So, there should be a speciﬁ  c emphasis on the toxicity of 
the “empty” non-drug loaded particles. This is especially 
important when slowly or non degradable particles are used 
for drug delivery which may show persistence and accumula-
tion on the site of the drug delivery, eventually resulting in 
chronic inﬂ  ammatory reactions.
Evidence for nanoparticle toxicity
The largest database on the toxicity of nanoparticles has origi-
nated from inhalation toxicology including the PM10 literature 
(particulate matter with a size below 10 mm), where the ‘NP 
hypothesis’ has proved to be a powerful drive for research 
(Donaldson et al 2002, 2004; Oberdörster, Oberdörster et al 
2005; Borm et al 2006). An overview of particle terminology 
in relation to ambient effects is given in Table 3. Therefore 
it relevant to discuss this evidence in the expectation that it International Journal of Nanomedicine 2008:3(2) 140
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will shed light on the toxicity of engineered NPs. The idea 
that combustion-derived NPs are an important component 
that drives the adverse effects of environmental particulate 
air pollution or PM10 comes from several sources:
1.  Much of the mass of PM10 is considered to be non-toxic 
and so there has arisen the idea that there is a component(s) 
of PM10 that actually drives the pro-inﬂ  ammatory effects 
and combustion-derived NP seems a likely candidate.
2.  Nanoparticles are the dominant particle type by number 
suggesting that they may be important and their small 
size means that they have a large surface area per unit 
mass. Particle toxicology suggests that, for toxic particles 
generally, more particle surface equals to more toxicity.
3.  Substantial toxicological data and limited data from 
epidemiological sources support the contention that NPs 
in PM10 are important drivers of adverse effects.
The adverse health effects of particulate matter (PM) are 
measurable as exacerbations of respiratory disease and deaths 
as well as hospitalizations and deaths from respiratory and 
cardiovascular disease (Dockery et al 1993; Brooke et al 
2004; Pope et al 2004). Inﬂ  ammation is the common factor 
that binds together these adverse effects and the ability of NPs 
to cause inﬂ  ammation can be seen as an important property. 
It is not clear what effects of NPs have pulmonary inﬂ  am-
mation as a prerequisite and what effects could potentially 
be driven by exposures below those causing inﬂ  ammation. 
There is also the potential for pulmonary inﬂ  ammation to 
result in changes in membrane permeability that in turn 
may impact the potential for particles to distribute beyond 
the lung. Some NPs may have the extra potential of affect-
ing cardiovascular disease directly. Vascular function was 
impaired after inhalation of diesel exhaust particles (Mills 
et al 2005). However, data to date are limited and not all 
studies of nanoparticles have shown signiﬁ  cant transloca-
tion from lung to the blood. In some studies translocation 
has been rather minimal (Kreyling et al 2002; Takenaka et al 
2006). Understanding clearance kinetics of inhaled ambient 
air nanoparticles will also be important in understanding their 
potential for adverse effects.
The current paradigm in particle toxicology is that 
ultraﬁ  ne ambient air particles have the potential of affecting 
cardiovascular disease both indirectly via pulmonary inﬂ  am-
mation and directly through particle distribution. Although 
important, this property of redistribution has yet to be dem-
onstrated for NPs present in real PM10. It should be noted 
that there are several mechanisms whereby NPs could lead 
to inﬂ  ammatory effects, as is the case for larger particles. 
These mechanisms are either based on the large surface area 
of particle core or on soluble components released by the NPs. 
In addition various chemicals including those of biological 
origin like endotoxin may be adsorbed onto the NP and 
released (Carty et al 2003; Kreyling et al 2004; Schins et al 
2004). Several toxicological studies support the contention 
that NPs in PM10 could drive inﬂ  ammatory effects. There are 
a number of components of PM10 that contribute to the mass 
but have little toxicity – these include salts such as sulfates, 
chlorides and ammonium salts and nitrates, but also wind-
blown or crustal dust. In fact within PM10 there are only 
few components that toxicologists would identify as likely 
mediators of adverse effects – ie, particle surfaces, organics, 
metals and endotoxin (in some PM10 samples). In fact, a 
large surface area, organics and metals are all characteristic 
of combustion–derived particles and so these have attracted 
considerable toxicological attention (Donaldson et al 2005). 
However, it is difﬁ  cult to untangle, in a combustion particle 
sample, the relative roles of surface, organics and metals, 
although this has been most attempted in vitro. The aggre-
gation of multiple chemical species including biological 
compounds like endotoxin limits the extrapolation of the 
results on the toxicological effects of such particles.
Toxicological effects of nanoparticles
As already mentioned above, NPs exert some very special 
properties that are very relevant in the further design of toxic-
ity testing of engineered nanomaterials. An overview of most 
Table 3 Various denominations of particles in inhalation toxi-
cology and drug delivery in relation to their source (ambient, 
bulk, engineered)
Particle type Description
PM10, PM 2.5 Particle mass fraction in ambient air with a mean 
diameter of 10 or 2.5 µm respectively. Basis of 
current standards for ambient particles in Europe 
and USA
Coarse particles The mass fraction of PM10, which is bigger than 
2.5 µm
Ultraﬁ  ne particles
(PM 0.1)
The fraction of PM10 with a size cut-off at 0.1  µm. 
Contains primary particles and agglomerates smaller 
than 100 nm.
PSP Poorly soluble particles with low speciﬁ  c toxicity. 
Maybe be ﬁ  ne or ultraﬁ  ne. Terminology used in 
relation to bulk synthetic particles. Examples: TiO2, 
carbon blacks, Amorphous silica, Iron oxides (Fe2O3), 
Zinc oxides (ZnO)
CDNP Combustion derived nanoparticles, such as diesel 
exhaust particles (DEP)
DEP Diesel exhaust particlesInternational Journal of Nanomedicine 2008:3(2) 141
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striking effects of (nano)particles that have been observed 
over the last decades is given in Table 4 along with the 
particle type that have been tested in this response. Several 
effects are just quantitatively different from ﬁ  ne particles. In 
this case nanoparticles may cause the same effects as ‘tradi-
tional’ particles (eg, inﬂ  ammation, lung cancer) but they may 
be more potent because of their greater surface area.
However, nanoparticles could also cause new types 
of effects not previously seen with larger particles (eg, 
mitochondrial damage, uptake through olfactory epithelium, 
platelet aggregation, cardiovascular effects). These effects 
depicted in Table 4 clearly need a new way of handling their 
toxicology. In addition, epidemiological evidence suggests 
that these effects occur predominantly in subjects that have 
an impaired health. This ﬁ  nding should be considered in 
developing toxicological testing models.
Effects on blood and cardiovascular system
As we discussed earlier, ligand coated engineered nanopar-
ticles are being explored and used as agents for molecular 
imaging or drug delivery tools. This has led to a considerable 
understanding of particle properties that can affect penetra-
tion in tissue without affecting tissue function. Cationic NPs, 
including gold and polystyrene have been shown to cause 
hemolysis and blood clotting, while usually anionic particles 
are quite non-toxic. This conceptual understanding maybe 
used to prevent potential effects of unintended NP exposure. 
Similarly, drug loaded nanoparticles have been used to 
prolong half-life or reduce side-effects and have shown which 
particle properties need to be modiﬁ  ed to allow delivery, 
while being biocompatible (Gupta and Gupta 2005).
On the other hand, one is trying to ﬁ  nd explanations for 
the increased risk of patients with cardiovascular diseases 
upon exposure to PM and/or trafﬁ  c. Several toxicological 
studies have demonstrated that combustion and model NPs 
can gain access to the blood following inhalation or instilla-
tion and can enhance experimental thrombosis but it is not 
clear whether this was an effect of pulmonary inﬂ  ammation 
or particles translocated to the blood (Nemmar et al 2002, 
2003; Mills et al 2005). High exposures to DEP by inhalation 
caused altered heart rate in hypertensive rats (Campen et al 
2003) interpreted as a direct effect of DEP on the pacemaker 
activity of the heart. Inﬂ  ammation in distal sites has long been 
associated with destabilization of atheromatous plaques and 
both instillation and inhalation of PM cause morphological 
evidence of atheromatous plaque increase and destabilization 
in rabbits (Suwa et al 2002) and mice (Chen and Nadziejko 
2005). Ultraﬁ  ne carbon black instilled into the blood has 
been reported to induce platelet accumulation in the hepatic 
microvasculature of healthy mice in association with pro-
thrombotic changes on the endothelial surface of the hepatic 
microvessels (Khandoga et al 2004). Recent studies with car-
bon derived nanomaterials showed that platelet aggregation 
was induced by both single and multi-wall carbon nanotubes, 
but not by the C60-fullerenes that are used as building blocks 
for these CNT (Radomski et al 2005). These data show that 
Table 4 Toxicity of engineered and combustion (nano) particles as illustrated by their most unique adverse effects in vivo and in vitro
Description of ﬁ  nding, in vivo Particle types
NPs cause pulmonary inﬂ  ammation in the rat
Later studies show that inﬂ  ammation is mediated by surface area dose.
All PSP
SWCNT, MWCNT
NPs cause more lung tumors than ﬁ  ne particles in rat chronic studies. Effect is surface area mediated PSP only
NPs cause progression of plague formation (ApoE -/- mice) SWCNT, PM2.5
NPs affect immune response to common allergens Polystyrene, CB, DEP
NsP can have access to systemic circulation upon inhalation and instillation. Speciﬁ  c NP,  dependent on 
surface coating
Description of ﬁ  nding, in vitro
NPs cause oxidative stress in vivo and in vitro, by inﬂ  ammatory action and generation of surface radicals. PSP, NP general, CNT
NPs inhibit macrophage phagocytosis, mobility and killing CB, TiO2
NPs cause platelet aggregation PM, SWCNT, fullerenes, 
latex-COOH surface
NPs exposure adversely affects cardiac function and vascular homeostasis PM, SWCNT
NPs interfere with Ca-transport and cause increased binding of pro-inﬂ  ammatory transcription factor NF-kB CB (100 nm), ROFA,
PM2.5
NPs can affect mitochondrial function Ambient NP, 
NPs can translocate to the brain from the nose MnO2, Au, carbon
NPs do affect rolling in hepatic tissue CBInternational Journal of Nanomedicine 2008:3(2) 142
De Jong and Borm
not all nanomaterials act similar in this test, and that surface 
area is not the only factor playing a role here. The data also 
corroborate the earlier concept developed in medicine that 
mainly cationic species have an effect on blood clotting. 
Interestingly, this is the ﬁ  rst study that allows bridging of 
data, since also a real life PM10 sample (SRM1648) was 
included in the test-series. Actually the PM sample showed 
a lower effect compared to the carbon nanotubes (Radomski 
et al 2005).
Uptake and effects of nanoparticles in the brain
Nanoparticles can get access to the brain by two different 
mechanisms, ie, (1) transsynaptic transport after inhalation 
through the olfactory epithelium, and (2) uptake through 
the blood-brain barrier. The ﬁ  rst pathway has been studied 
primarily with model particles such as carbon, Au and MnO2 
in experimental inhalation models in rats (Oberdörster et al 
2004; Oberdörster, Oberdörster et al 2005). The second 
pathway has been the result of extensive research and 
particle surface manipulation in drug delivery (Kreuter 
2001; Koziara et al 2006; Tiwari and Amiji 2006). The 
latter studies suggest that the physiological barrier may 
limit the distribution of some proteins and viral particles 
after transvascular delivery to the brain, suggesting that 
the healthy BBB contains defense mechanisms protect-
ing it from blood borne nanoparticle exposure. When 
nanoparticles with different surface characteristics were 
evaluated, neutral nanoparticles and low concentrations of 
anionic nanoparticles were found to have no effect on BBB 
integrity, whereas high concentrations of anionic nanopar-
ticles and cationic nanoparticles were toxic for the BBB. 
Nanoparticles have been shown to induce the production of 
reactive oxygen species and oxidative stress (Nel et al 2006) 
and this has been conﬁ  rmed in the brain after inhalation of 
MnO2 nanoparticles (Elder et al 2006). Oxidative stress has 
been implicated in the pathogenesis of neurodegenerative 
diseases such as Parkinson’s and Alzheimer’s diseases. 
Evidence for the involvement of ambient air nanoparticles 
in these effects is presented by studies in biopsies from city 
dwellers. Alzheimer’s like pathology was demonstrated in 
brain sections by increased markers of inﬂ  ammation and 
AB42-accumulation in frontal cortex and hippocampus 
in association with the presence of nanoparticles (Calde-
ron-Garciduenas et al 2004). Also inhalation exposure of 
BALB/c mice to particulate matter showed activation of 
pro-inﬂ  ammatory cytokines in the brain (Campbell et al 
2005). Whether this is due to the fraction of combustion 
nanoparticles remains to be investigated.
Current data on the toxicology 
engineered nanoparticles
In the past few years a number of papers have described the 
toxicology of newly engineered nanomaterials, including 
fullerenes (Sayes et al 2005), carbon nanotubes (Donaldson 
et al 2006), quantum dots (Hardman 2006) and have illus-
trated that apart from size and surface area, many more 
parameters describing the material (surface) properties have 
to be included. In a recent report Costigan (2006) reviewed 
the evidence for toxicity of NPs used in healthcare products. 
Her conclusions again stressed the limited availability of 
toxicity data of the NPs in use.
Carbon nanotubes
Carbon nanotubes are long carbon-based tubes that can 
be either single- or multiwalled and have the potential to 
act as biopersistent ﬁ  bers. Nanotubes have aspect ratios 
100, with lengths of several mm and diameters of 0.7 to 
1.5 nm for single-walled carbon nanotubes (SWCNT) and 
2 to 50 nm for multiwalled carbon nanotubes (MWCNT). 
In vitro incubation of keratinocytes and bronchial epithelial 
cells with high doses of SWCNT results in ROS generation, 
lipid peroxidation, oxidative stress, mitochondrial dys-
function, and changes in cell morphology (Shvedova et al 
2003; Sayes et al 2006). Recent studies with carbon derived 
nanomaterials showed that platelet aggregation was induced 
by both single and multi-wall carbon nanotubes, but not 
by the C60-fullerenes that are used as building blocks for 
these CNT (Radomski et al 2005). MWCNT also elicit pro-
inﬂ  ammatory effects in keratinocytes (Monteiro-Riviere 
et al 2005). Several studies using intratracheal instillation 
of high doses of nanotubes in rodents demonstrated chronic 
lung inflammation, including foreign-body granuloma 
formation and interstitial ﬁ  brosis (Warheit et al 2004; 
Muller et al 2005). In two in vivo studies SWCNTs were 
demonstrated to induce lung granulomas after intratra-
cheal administration (Lam et al 2004; Warheit et al 2004) 
indicating that these nanotubes can not be classiﬁ  ed as a 
new form of graphite on material safety data sheets. On a 
dose per mass basis the nanotubes were more toxic than 
quartz particles well known for their lung toxicity. Carbon 
black, carbonyl iron and graphite produced no signiﬁ  cant 
adverse effects (Lam et al 2004; Warheit et al 2004). 
These studies also reveal the tendency of the nonphysi-
ologic administration route and the unrealistic high doses 
to lead to asphyxiation through nanotube clumping in the 
airways (Warheit et al 2004; Muller et al 2005). Although 
it has been suggested that the granulomatous inﬂ  ammation International Journal of Nanomedicine 2008:3(2) 143
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could be a biopersistent ﬁ  ber effect, the high dose of the 
aggregated nanotubes and the presence of metal impurities 
(eg, Fe) could account for artiﬁ  cial toxicity.
Fullerenes
Fullerenes are being explored as potential new antimicrobial 
agents in view of their potency for induction of reactive 
oxygen species after photoexcitation (Yamakoshi et al 2003). 
However, this may have an impact on microbial communities 
if they are released into the environment via efﬂ  uents. There-
fore, various studies with fullerenes have been published 
with regard to the ecotoxicity of these important building 
blocks in nanomaterials. Tests with un-coated, water soluble, 
colloidal fullerenes (nC60) show that the 48-hour LC50 in 
Daphnia magna varied form 460 to 800 ppb (Lovern and 
Klaper 2006; Zhu et al 2006), using standard EPA protocols. 
However, for sonicated C-60 fullerenes the LC50 was one 
order of magnitiude higher with 7.9 ppm (Lovern and Klaper 
2006). In largemouth brass, although no mortality was seen, 
lipid peroxidation was seen in the brain and glutathione 
depletion in the gill after exposure to 0.5 ppm nC60 for 
48 hours (Oberdörster 2004). There are several hypotheses 
as to how lipid damage may have occurred in the brain, 
including direct redox activity by fullerenes reaching the 
brain via circulation or axonal translocation and dissolving 
into the lipid-rich brain tissue, oxygen radical production by 
microglia, or production of reactive fullerene metabolites by 
cytochrome P450 metabolism.
Dendrimers
Because of their speciﬁ  c nature dendrimers are speciﬁ  cally 
suited for drug delivery purposes. Although their small 
size (up to 10 nm) limits extensive drug incorporation 
into the dendrimers, their dendritic nature and branching 
allows for drug loading onto the outside surfaces of the 
polymeric structure (Svenson and Tomalia 2005). Func-
tionalization of the surface with speciﬁ  c antibodies may 
further enhance potential targeting. Apart from applica-
tion in drug-delivery, dendrimers are being investigated 
for many other uses including bacterial cell killing, as 
gene transfer agents and trans-membrane transport. Little 
published data is available on the toxicity of this class of 
particles. A recent review on this topic (Duncan and Izzo 
2005) concluded that it will only ever be possible to des-
ignate a dendrimers as “safe” when related to a speciﬁ  c 
application. The so far limited clinical experience with 
dendrimers makes it impossible to designate any particular 
chemistry intrinsically “safe” or “toxic”.
Quantum dots
Quantum dots are a heterogeneous group of nanoparticles 
(reviewed by Hardman 2006). Quantum dot absorption, dis-
tribution, metabolism and excretion, and therefore also quan-
tum dot toxicity, depend on multiple factors derived from 
both inherent physicochemical properties and environmental 
conditions. Quantum dots may vary in size ranges from 2.5 up 
to 100 nm, depending on coating thickness. Studies speciﬁ  -
cally performed to investigate quantum dot toxicity are few 
(Hardman 2006). In vitro studies have indicated that quantum 
dots may be toxic (Hoshino et al 2004; Shiohara et al 2004; 
Lovric, Bazzi et al 2005) of which some toxicity could be 
attributed to the surface coating (Hoshino et al 2004, 2007). 
Choi et al (2007) demonstrated that quantum dot toxicity was 
reduced after surface modiﬁ  cation with N-acetylcysteine, 
while the non modiﬁ  ed cadmium telluride quantum dots 
induced lipid peroxidation in the cells. Lovric, Cho et al 
(2005) showed “naked” quantum dots to be cytotoxic by 
induction of reactive oxygen species resulting in damage to 
plasma membranes, mitochondria and nucleus. As it is the 
bioactive coating which allows the use of quantum dots for 
speciﬁ  c targeting to cells and/or cell organelles, attention is 
warranted in using the surface molecules in terms of induc-
tion of toxic effects. However, also the quantum dot core 
material has an effect on the toxic potential of the quantum 
dots as for cadmium containing quantum dots the toxicity 
was suggested to be due to release of highly toxic free Cd2+ 
ions (Derfus et al 2004; Kirchner et al 2005). For quantum 
dots composed of cadmiun/telluride cellular toxicity was 
found but not for cadmium selenium/zinc sulfate quantum 
dots (Cho et al 2007). On the other hand Hardman (2006) 
also reported on studies demonstrating a lack of both in vitro 
and in vivo toxicity. However, before there can be a respon-
sible development of quantum dots with minimal risks more 
information on toxicological risks needs to be provided.
Gold nanoparticles/nanoshells
In the summary of evaluations performed by the Joint FAO/
WHO (Food and Agriculture Organization of the United 
Nations/World Health Organization) Expert Committee on 
Food Additives (JECFA) gold was not considered to pres-
ent a hazard when used as coloring agent and food additive 
(JECFA 2001). However, such evaluations did not consider 
nanoformulations of gold. Metallic colloidal gold nanopar-
ticles are widely used, can be synthesized in different forms 
(rods, dots), are commercially available in various size 
ranges and can be detected at low concentrations. Cells can 
take up gold nanoparticles without cytotoxic effects (Connor International Journal of Nanomedicine 2008:3(2) 144
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et al 2005; Shenoy et al 2006). For biomedical applications, 
they are used as potential carriers for drug delivery, imaging 
molecules and even genes (Kawano et al 2006), and for the 
development of novel cancer therapy products (Hirsch et al 
2003; Hainfeld et al 2004; Loo et al 2004; O’Neal et al 2004; 
Radt et al 2004). For gold nanorods the cytotoxicity could be 
attributed to the presence of the stabilizer CTAB of which 
even residual presence after washing resulted in considerable 
cytotoxicity. PEG-modiﬁ  ed gold nanorods with removing 
the excess CTAB did not show cytotoxicity (Niidome et al 
2006). In an acute oral toxicity study no signs of gross toxicity 
or adverse effects were noted when a nanogold suspension 
(nanoparticle diameter ca. 50 nm) was evaluated, the single 
dose for acute oral LD50 being greater than 5000 mg/kg body 
weight (Lai et al 2006).
Gold solutions are also used to prepare nanoshells 
composed of gold and copper, or gold and silver to function 
as contrast agents in Magnetic Resonance Imaging (RMI) 
(Su et al 2006), and gold-silica for photothermal ablation of 
tumor cells (Bernardi et al 2007; Stern et al 2007). In vitro 
the non targeted nanoshells did not show cytotoxicity for 
the tumor cells, whereas after binding to the tumor cells cell 
death could be obtained after laser activation (Lowery et al 
2006; Bernardi et al 2007; Stern et al 2007). Also in vivo 
positive results were obtained with photothermal ablation 
therapy in a mouse model for colon carcinoma after intra-
veneous administration of PEG coated gold nanoshells of 
approximately 130 nm (O’Neal et al 2004).
Silica
For silica nanoparticles both in vitro toxic and non toxic 
responses were observed. Both 15 nm and 46 nm silica 
nanoparticles showed similar dose dependent cytotoxicity 
in vitro (Lin et al 2006). There was an increase in toxicity 
both at increasing doses and at increasing exposure time 
(24, 48, and 72 h). SiO2 exposure resulted in an increased 
ROS levels and reduced glutathione levels indicating an 
increase in oxidative stress. Also Chang et al (2007) found 
silica nanoparticles to be toxic at high dosages as shown by 
a reduction in cell viability/cell proliferation and by lactate 
dehydrogenase (LDH) release from the cells indicating 
membrane damage. Cells with a long doubling time were 
more susceptible for the cytotoxic effects of the silica 
nanoparticles than cells with short doubling times (Chang 
et al 2007). In another study only at concentrations above 0.1 
mg/ml a signiﬁ  cant reduction in cell viability was observed 
(Jin et al 2007). In addition, an alveolar macrophage cell line 
(MHS) was found to be more susceptible for nanaoparticle 
induced cytotoxicity than a lung epithelial cell line (A549) 
which was suggested to be due to the phagocytic properties 
of the macrophage cell line. Cell death was probably 
not caused by apoptosis (Jin et al 2007). In contrast for 
cationic silica nanoparticles using amino-hexyl-amino-
propyltrimethoxysilane as a surface modiﬁ  cation low or no 
cell toxicity was observed (Ravi Kumar et al 2004).
Nanomaterials in medicine: needs
Although there is a considerable amount of data on the tox-
icity of NPs, this data is mainly based on a small panel of 
NPs (combustion derived NPs, TiO2, CB) and the assump-
tion that a lot of effects by particulate matter are driven by 
the ultraﬁ  ne particle fraction in it (Donaldson et al 2002; 
Oberdörtster, Oberdörster et al 2005; Borm and Muller-
Schulte 2006). In most studies the nanoparticles were used 
as a model for ambient air particle toxicity. One of the more 
general conclusions is that indeed there is a clear tendency 
for very small (nano)particles to be more toxic than larger 
particles with the same chemical composition.
For nanoformulations used in drug delivery the focus in 
most papers is mainly on obtained reduction of toxicity of 
the incorporated drug, whereas the possible toxicity of the 
carrier used is not considered. Especially possible residues of 
such a treatment may harbor potential local and/or systemic 
toxic responses.
For medical applications certain routine assays need to be 
performed which will detect a number of potential hazards. 
However, it can be anticipated that not all hazards are at 
this moment known for the use of nanoparticles. In a recent 
report Costigan (2006) reviewed the evidence for toxicity 
of NPs used in healthcare products. Her conclusions again 
stressed the limited availability of toxicity data of the NPs in 
use. However, in NPs for healthcare products most if not all 
mechanisms of toxicity could be identiﬁ  ed by conventional 
hazard identiﬁ  cation testing as currently required to com-
ply with the regulations for healthcare products (Costigan 
2006). Costigan identiﬁ  ed four possible mechanisms of NP 
toxicity, being chemical toxicity of one of the constituents 
with the same mode of action as the bulk chemical, toxicity 
due to degradation products, toxicity due to endocytosis of 
the NPs, and membrane lysis due to the NPs possibly via 
chemical toxicity.
Although hazard identiﬁ  cation is the general approach 
for safety evaluation of healthcare products, it is recom-
mended to add testing driven by the anticipated application 
and classiﬁ  cation by risk. Some engineered NPs, which 
get airborne will pose inhalation hazards, while cosmetics International Journal of Nanomedicine 2008:3(2) 145
Drug delivery and nanoparticles
with NPs provide dermal exposures. For parenteral use 
interactions with blood components, systemic distribution 
and kinetics are of importance, when engineered NPs are 
being used as devices to target drugs to speciﬁ  c tissues, to 
increase their biological half time, or for imaging purposes. 
Each nanoparticle formulation should be tested on a case 
by case basis in the requisite ways focusing on their portal 
of entry. In this respect also the potential adverse (toxic) 
effects of empty particles should be considered. In devel-
oping testing procedures and protocols a number of basic 
issues need to be considered:
1.  Which effects are speciﬁ  c for nanomaterials, and which 
effects are merely stronger? Nanoparticles may cause the 
same effects as ‘traditional’ particles (eg, inﬂ  ammation, 
lung cancer) but they may be more potent because of their 
greater surface area. Nanoparticles could also cause new 
types of effects not previously seen with larger particles 
or bulk chemicals.
2.  Can we extrapolate available data and concepts? The epi-
demiological evidence on ultraﬁ  ne particles has revealed 
several effects, mechanisms of action and susceptible 
groups upon inhalation of ultraﬁ  ne particles. Whether 
these concepts can be used for nanoparticles released 
from manufactured nanomaterials is yet unknown.
3.  Is our current regulation robust enough to handle risks 
of nanomaterials? We deal with a growing set of materi-
als of which the properties are largely unknown and for 
which current testing procedures and legislation might 
produce false negatives and/or false positives. The central 
question here is whether current testing and classiﬁ  ca-
tion protocols are appropriate or sufﬁ  cient. These will 
detect certain toxic effects as demonstrated by the studies 
already published. However, it can be anticipated that 
not all hazards will be detected and additional speciﬁ  c 
testing may be needed. Nanotechnology also promotes 
convergence of technologies, and for example similar 
materials may be applied in the automotive and the life 
sciences sector. To stimulate production and marketing 
of safe nanomaterials exchange of data between sectors 
is recommended. Sharing of information on the toxicity 
of nanomaterials, will signiﬁ  cantly reduce time to market 
for many products and producers.
4.  Should we use the precautionary principle in current 
regulatory testing? The precautionary principle (PP) 
is a highly debated issue in international politics and 
was ﬁ  rst added in EU environmental regulation in the 
Maastricht treaty in Article 174 (ex Art 130r). The 
PP points out that scientiﬁ  c uncertainty is no reason 
for inaction if there might be strong adverse effects. 
It has been criticized for being too vague and too 
arbitrary to form a basis for rational decision-making. 
On the other hand the PP does not necessarily imply 
a complete ban of substances but may be applied in 
steps of decreasing uncertainty or perceived risk. It is 
typically applied where scientiﬁ  c information is insuf-
ﬁ  cient, inconclusive or uncertain whilst at the same 
time there are indications that potential effects may 
occur. Approaches in risk governance range from early 
explorations by Swiss RE (Hett 2004) to more recent 
detailed reviews such by Renn and Roco (2006) and 
the Health Council of the Netherlands (2006). A crucial 
difference between both reports is that Renn and Roco 
place the nanotechnology products themselves into 
the risk issue categories rather than the risk issues that 
accompany the use of these products. This difference 
may seem trivial, but is important since it is the purpose 
and application rather than the device itself that connect 
hazard to exposure, and therefore creates a risk. For 
example, it fails to distinguish between brain implants 
for enhancement purposes and those for ﬁ  ghting tremor 
in Parkinson patients. This may pave the way to one 
nanotechnology product compromising or allowing all 
the others. Furthermore, it can convey the impression 
that the broader societal implications and accompany-
ing ethical issues of nanotechnologies are as new as the 
nanotechnology products themselves, or even are still 
in the future. However, most of them are not.
Conclusions
The use of Nanotechnology in medicine and more speciﬁ  -
cally drug delivery is set to spread rapidly. For decades 
pharmaceutical sciences have been using nanoparticles to 
reduce toxicity and side effects of drugs. Up to recently 
it was not realized that these carrier systems themselves 
may impose risks to the patient. The type of hazards that 
are introduced by using nanoparticles for drug delivery 
are beyond that posed by conventional hazards imposed 
by chemicals in delivery matrices. However, so far, the 
scientiﬁ  c paradigm for the possible (adverse) reactivity of 
nanoparticles is lacking and we have little understanding 
of the basics of the interaction of nanoparticles with living 
cells, organs and organisms. A conceptual understanding of 
biological responses to nanomaterials is needed to develop 
and apply safe nanomaterials in drug delivery in the future. 
Furthermore a close collaboration between those working 
in drug delivery and particle toxicology is necessary for International Journal of Nanomedicine 2008:3(2) 146
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the exchange of concepts, methods and know-how to move 
this issue ahead.
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